Implementation of a Multiprofessional Competence and Consultation Center for Optimizing Medication Safety in Oral Antitumor Therapy: Patient Surveys and Analysis of Drug-related Problems

Implementation of a Multiprofessional Competence and Consultation Center for Optimizing Medication Safety in Oral Antitumor Therapy: Patient Surveys and Analysis of Drug-related Problems - AMBORA - Competence Center for Medication Safety in Oral Antitumor Therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00026272

Enrollment

500

Registered

2021-10-04

Start date

2021-07-12

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

all tumor entities treated with an oral antitumor drug C00-D48

Interventions

Group 1: intensified clinical pharmacological/pharmaceutical care program

questionnaires (e.g. SIMS-D, EORTC QLQ-C30, PRO-CTCAE)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: existing therapy with an oral anticancer agent or initiation of therapy with an oral anticancer agent, treatment at the CCC Erlangen-EMN or cooperating practices, ability to complete questionnaires

Exclusion criteria

Exclusion criteria: lack of german language skills (in written or spoken form), cognitive impairment, non-consenting patients, missing written consent

Design outcomes

Primary

Measure	Time frame
At least 70 % of patients treated with oral antitumor drugs at the CCC Erlangen-EMN are counselled by the Competence and Consultation Center for Medication Safety. (descriptive)	—

Secondary

Measure	Time frame
e.g. rates and severity of side effects (questionnaire), health-related quality of life (questionnaire), patient knowledge (questionnaire), medication errors (descriptive) number of referring institutions and physicians (descriptive)	—

Countries

Germany

Contacts

Public ContactLisa Cuba

Apotheke des Universitätsklinikums Erlangen; Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie der FAU Erlangen-Nürnberg

lisa.cuba@fau.de+49(0)91318522542

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026